Beacon Medicare Limited, pioneer of oncology products manufacturer and one of the leading and fastest growing pharmaceutical companies in Bangladesh, participated in the AORTIC’s international conference on cancer in Mozambique last year. The 12th AORTIC conference was held with the theme Cancer in Africa: Innovation, Strategies and Implementation, in Maputo, the capital and most populous [...]
Beacon Medicare Ltd. has attended in the Kenya Liver Disease Conference of Kenya, held in Nairobi from 13th to 15th September, 2018. More than thousand doctors around the African community have attended in the conference. Beacon was one of the key sponsors for this event. Beacon is pioneer in producing generic lifesaving hepatitis drugs. African [...]
The Annual Business Conference of Sri Lankan team of Beacon was held in Beacon Business Centre on 1st February 2019. The Sri Lankan sales team and the head office officials of Beacon Medicare Ltd. were present at the conference. The team celebrate their achievement in Bali Indonesia from 1st to 5th February,2019.
Beacon team holds the No.1 position among oncology companies of Nepal. Team Nepal is a role model of marketing for Beacon Medicare Ltd. The Nepal team shared their success of 2018 and strategies for 2019 in the conference which was held in Beacon Business center, Dhaka, Bangladesh. The team celebrated their achievement in Bangkok, Thailand. [...]
Beacon Medicare Ltd. was the very successful business wing of Beacon Group in 2018. The team has been celebrated their achievement in Egypt & Dubai from 23 January 2019 to 29 January 2019. Figure 1:BML team infront of the Pyramid Khufu. Figure-2:BML team in Dubai Miracle Garden.
In 29th December, 2017 the annual conference of BEACON Medicare Limited held in Istanbul, Turkey. Chairman of Beacon Group Md. Ebadul Karim, Managing Director Niazul karim , Executive Vice President Monjurul Alam, Sr.Manager Md.Sahariar Tamal Selim and all the Global business executives were present there. In this conference Managing Director Niazul Karim declared that "considering the huge [...]
The Annual conference of Business Development Department of BEACON Pharmaceuticals Limited (BPL) was held in Bali, Indonesia on 31st December, 2016 The conference theme was “Caring Globally”. In the opening speech the Managing Director of BEACON, Md. Ebadul Karim advised BDD members to work hard to make BEACON’s product available to global patients specially who [...]
Like-wise number one in Oncology, Beacon Pharmaceuticals Limited is the first company in Bangladesh who is proudly exporting Hepatitis C generic medicine more than 45 countries around the Globe. Under the patient support program Beacon Pharmaceuticals Limited can deliver their generic medicine to everyone everywhere around the world. The countries under the coverage of BEACON [...]
Beacon Pharmaceutical has received registration of two more products Prasugrel 5 and 10 in Myanmar. Prasugrel is used for prevent thrombosis (blood clotting). It acts as a platelet inhibitor. Besides Prasugrel, Beacon has registered 20 Products in Myanmar. Azithromycin 500 mg Injection (Brand: Simpli-3) Baclofen 10 mg Tablet (Brand: Flexibac) Iron (100 mg elemental iron) [...]
Beacon Pharmaceutical and their Nepal partner, Prime Care International Pvt. Ltd have jointly organized the Annual sales conference 2015 at Cox’s Bazar, Bangladesh. Directors of Prime Oncology Manager of Beacon Oncology, Nepal and Hi-officials of Business Development Dept. were present in the Conference. Performance of 2015 and budget and planning for 2016 were discussed in [...]
Beacon Pharmaceuticals limited and their Sri Lanka partner, Emerchemie has organized a seminar on targeted cancer Therapy at Hotel Cinnamon Lake Colombo. Dr. Foo Sr. consultant oncology Mount Elizabeth Hospital, Singapore was the key note speaker in the seminar. Dr. Foo has expressed his satisfaction of clinical success by using erlotinib in lung cancer, sunitinib [...]
Daclavir (Daclatasvir) is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is the first-ever approved HCV NS5A replication complex inhibitor, meaning it interferes with a protein the virus uses to reproduce. Daclavir (Daclatasvir) should be combined with other medications, which may include other direct-acting [...]
